SOURCES SOUGHT
D -- Sources Sought Notice: Access to Data on Health Care Practitioner Prescribing Practices
- Notice Date
- 6/28/2017
- Notice Type
- Sources Sought
- NAICS
- 518210
— Data Processing, Hosting, and Related Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-17-SS-1185455
- Archive Date
- 7/21/2017
- Point of Contact
- Christopher R. McGucken, Phone: (240) 402-7566
- E-Mail Address
-
christopher.mcgucken@fda.hhs.gov
(christopher.mcgucken@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Notice: Access to Data on Health Care Practitioner Prescribing Practices MARKET RESEARCH PURPOSES ONLY NOT A REQUEST FOR PROPOSAL OR SOLICITATION The U.S. Food and Drug Administration (FDA), Office of Acquisitions and Grants Services (OAGS) is conducting market research to support the Center for Drug Evaluation and Research (CDER) requirement for access to real-time, unlimited, immediate, direct, multi-user, access to currently existing data healthcare practitioner prescribing practices. Please note that the FDA is not interested in developing this database and expect any qualified organization to own the data as well as the means to access the data. This is a Sources Sought notice to determine the availability of Small Businesses capable of supplying the required supply item/services. This notice is for planning purposes only, and does not constitute an invitation for Bids, Request for Proposal or Request for Quotation or an indication the Government to award a contract, nor does the Government intend to pay for any information submitted as a result of this notice. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. Scope of Work: Contractor's respondent to this notice shall have the capabilities to furnish the necessary personnel, materials, services, equipment, facilities, and otherwise do all things necessary for the performance of the work described below. Capabilities Required: The Contractor shall have the capability to provide continuous access to data resources on health care practitioner prescribing practices including, but not limited to drug treatment patterns, patient demographics, and indications for treatment in the outpatient setting. The source data can be obtained from a survey of healthcare practitioner prescribing practices. FDA requires access to such data to obtain national estimates or counts. The FDA has no interest in knowing the identity of any patient, provider, or health plan included in the data. It shall be solely the Contractor's responsibility to de-identify the data for FDA use. For survey data, the Contractor shall have the capability to project the data to the national level using a FDA approved projection or other appropriate methodology. Results from projections shall be comparable to estimates obtained from national benchmarks such as the National Center for Health Statistics' National Ambulatory Medical Care Survey (NAMCS). The data resource(s) shall have raw and projected numbers. These data resources shall have the capability to be accessible via a secure Internet or network-based method permitting simultaneous, multi-user access through a user friendly data query tool(s). The health care practitioners (e.g., physicians, physician assistants, nurse practitioners, dentists) prescribing practices data shall have the capability to include visits and patients; characterization of individual health care practitioners in terms of number, specialty, practice setting, age, gender, and U.S. Census region. Additionally, these data offered shall provide health care practitioner prescribing practices data in terms of type of facility (e.g., surgi-centers, staff model HMOs, clinics), and U.S. Census region and where possible, the contractor shall provide a comparison to national figures. The patient-specific population data shall have the capability to include the number and percent of patient populations of special interest to the FDA, including children (≤ 17 years), infants (<1 year), women of childbearing age, and elderly (≥ 65 years); the health care practitioner turnover rate for participation in the data resource; and the demographic distribution of patients (age and gender required; race, if available). The patient-specific basic data elements at the visit-level shall have the capability to include (but are not limited to): patient demographics such as age (specify method by which age is obtained and how it is displayed in canned reports, i.e. standard age groups, customized age groups, single years), gender and specify if other data elements are available which would include race/ethnicity; height and weight; clinical measures, such as blood pressure, cholesterol, smoking status; type of insurance; and U.S Census region. The drug-specific basic data elements shall have the capability to include generic/trade name of drug; linkage between generic and established name; strength; dosage form; new vs. continued therapy; days' supply; prescriber specialty; quantity prescribed; directions for use; indication(s) for use, and source of drug (sample provided, prescription given, product administered). The diagnosis-specific basic data element shall have the capability to describe the patient's condition as identified by the health care practitioner during the time of office-visit; as well as visit-specific basic data elements with the time of visit (month, year); the type of visit, e.g., first vs. subsequent visit; and the type of outpatient setting and the health care practitioner-specific basic data elements shall include the type of practitioner; specialty; age; gender; and U.S Census region. The data resource shall have the capability to include a drug coding system that consists of drug, clinical, or medical coding levels for FDA data analyses, quantify the prescribing of drug- or biologic products in the outpatient setting by healthcare professionals. For examining visit-level prescribing data for products, the data resource shall link clinical or medical data to indication in detail. For examining data on visits for specified disease or medical conditions, and associated treatments (if any), the data resource shall capture the drugs prescribed to treat the same diagnosis as well as all drugs mentioned during the visit regardless of diagnosis. Capability Statements: Responses to this sources sought shall unequivocally demonstrate the respondent's capabilities to provide the services/data above. Though the target audience is small business, all interested parties may respond. At a minimum, responses shall include the following: 1. Business name and bio, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, SDB, WOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address. Provide this same information again if responding to provide a service offered by another firm. 2. Past Performance information shall include date of services, description, dollar value, client name, client address, client contact name, client point of contact mailing address (if different from that provided for client), client point of contact phone number, client point of contact email address, and name of company (to include DUNS number and size status) if not the respondent. 3. Descriptive literature, brochures, marketing material, etc. detailing the nature of services the responding firm is regularly engaged in providing. 4. If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this potential requirement are also requested. If a large business, provide if subcontracting opportunities exist for small business concerns. The Government is not responsible for locating or securing any information, not identified in the response. Response Instructions: Interested parties shall respond with capability statements in person, by e-mail, fax, mail or other delivery method before 1:00 PM Eastern Time on July 6th, 2017 to Christopher.mcgucken@fda.hhs.gov. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre‐solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non‐proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-17-SS-1185455/listing.html)
- Record
- SN04560867-W 20170630/170628234718-0b325142b934b5d26cd3c43d0799690b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |